The Mission of the ARMI Research Collaborative, Inc. (“ARC“) is to accelerate equitable adoption of advanced enabling technologies for the biofabrication of cells, tissues, and organs and provide access to advanced biofabrication facilities for promising biofabricated research projects. ARC will focus on providing access to cutting-edge technology to provide better opportunities for researchers and students to advance promising technologies.
ARC is a wholly-owned subsidiary of the Advanced Regenerative Manufacturing Institute, Inc. (“ARMI“) and is an important part of ARMI’s mission is to advance the bioeconomy of the United States by creating a robust, highly diverse, competitive, capable and innovative domestic cell, tissue, and organ manufacturing ecosystem that will fundamentally change healthcare for chronic disease and traumatic injury and the trained and ready workforce essential for that ecosystem. It has become clear as we work to fulfill our goal of creating a domestic cell, tissue, and organ manufacturing ecosystem to address the medical needs of Americans with chronic disease and traumatic injury, including our military and veterans that a separate, affiliated organization that is tax-exempt under Code Section 501(c)(3) – ARC — would allow ARMI to focus on its core mission and allow ARC to focus on expanding access to advanced enabling technologies for researchers and students underrepresented in biotechnology.
ARC plans to develop a competitive research grant program to fund biomanufacturing research to empower a diverse community of investigators to build enhanced expertise and grow their institutions’ capabilities. All grant recipients will be institutions of higher education that are tax-exempt under Code Section 501(c)(3).
